---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006056"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:57:07.684183+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints

## Summary
- Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.
- Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.
- Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.
- Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.
- First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted.

## SEC filing metadata
- accession: 0001171843-24-006056
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/0001171843-24-006056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/f8k_110624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006056
- JSON: https://secwatch.observer/filing/0001171843-24-006056.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.